BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2014 3:23:00 PM | Browse: 1476 | Download: 1601
 |
Received |
|
2012-11-17 00:06 |
|
Peer-Review Started |
|
2012-11-19 15:32 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2012-11-27 17:57 |
|
Revised |
|
2012-12-11 23:48 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2013-01-21 09:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2013-01-21 12:51 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2013-03-12 10:35 |
|
Publish the Manuscript Online |
|
2013-03-14 19:50 |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wolfgang Scheppach, Nikolaus Reissmann, Thomas Sprinz, Ekkehard Schippers, Bjoern Schoettker and Justus G Mueller |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wolfgang Scheppach, MD, Department of Medicine, Juliusspital Wuerzburg, Juliuspromenade 19, D-97070 Wuerzburg, Germany. gastroenterologie@juliusspital.de
|
| Key Words |
Perivascular epithelioid cell tumor; Colon; Liver metastases; Mammalian target of rapamycin inhibitor; Sirolimus; Chemotherapy; Doxorubicin; Ifosfamide |
| Core Tip |
|
| Publish Date |
2013-03-14 19:50 |
| Citation |
Scheppach W, Reissmann N, Sprinz T, Schippers E, Schoettker B, Mueller JG. PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide. World J Gastroenterol 2013; 19(10): 1657-1660 |
| URL |
http://www.wjgnet.com/1007-9327/full/v19/i10/1657.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v19.i10.1657 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
